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Organophosphates (OPs), discovered more than 100
years ago, are the predominant group of insecticides
used for pest control. Today, OPs are used worldwide
in agriculture as well as in most household gardens.
This ease of availability of the compounds has resulted
in a gradual increase in accidental and suicidal poi-
soning, mainly in developing countries. OP pesticides
inhibit acetylcholinesterase (AChE) at the muscarinic
and nicotinic synapses by depositing a phosphoryl
group at the enzyme’s active site. This results in an
accumulation of acetylcholine and uncontrolled activa-
tion of cholinergic synapses. Acute organophosphate
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Poisoning due to organophosphate pesticides is an important cause of morbidity and mortality
worldwide. Although standard treatments involving the administration of atropine and oximes
have been used, there remain many controversial areas concerning organophosphate poisoning
(OPP). Herein, we present our 10 years of experience in assessing the severity of OPP in southern
Taiwan. A retrospective study was performed on patients admitted with OPP. A total of 75 patients
(50 males and 25 females) were studied between January 1996 and December 2005. Diagnosis was
based on a clinical assessment and serum acetylcholinesterase (AChE) level at the time of hospital
admission. The severity of OPP was assessed using the grading system of Bardin et al. The duration
and dosage of atropine and palidroxime were recorded. All the biochemical data were analyzed.
Sixty-one of the patients had attempted suicide and 14 patients had accidental exposure. The overall
mortality rate was 8%. Muscarinic effects were observed in 66 (88%) of the OPP patients and the
most frequent symptom was bronchial hypersecretion (52%). Among these three different severity
groups, prolonged length of stay, higher infection rates, and higher mortality were found in the life-
threatened group. The initial serum C-reactive protein (CRP) level was strongly correlated to the
severity grading of the OPP. Nearly half of the patients were admitted to the intensive care unit
(ICU) and, of this, 21 patients developed respiratory failure within 72 hours. Low serum AChE levels
support the diagnosis of OPP, but no significant association was found between the severity of OPP
and serum AChE levels. The grading system of Bardin et al is very helpful for physicians to facilitate
the recognition of seriously poisoned subjects, and to permit their early admission to an ICU.
Initial serum CRP, an acute phase reactant, had significant value in assessing the severity of the OPP.
Although the management of acute OPP is supportive and the recovery rate is high, anti-cholinergic
therapy should be used as soon as possible to counteract muscarinic effects. Physicians must be aware
of the potential dangers of respiratory failure, which could occur within 72 hours of OPP.
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poisoning (OPP) causes tens of thousands of deaths
each year across the world. The mortality rate of acute
OPP is 10–20% [1–3] and the World Health Organiza-
tion (WHO) has estimated that 200,000 people die
each year from pesticide poisoning.
Signs of OPP are classified into effects secondary to
muscarinic, nicotinic, and central nervous system (CNS)
receptors being over-stimulated by the accumulation
of acetylcholine at the synapses. A decrease in plasma
AChE is usually used as confirmation of OPP, but the
correlation between the enzyme level and the severity
of clinical symptoms is poor. Atropine and oximes are
the main treatment drugs. Atropine is used to counter-
act muscarinic effects such as bronchial hypersecretion,
lacrimation, and bradycardia, but there is still much
controversy about the therapeutic effect of oximes.
In this article, we report our 10 years of experience
in the management of OPP. Although several scoring
systems have been developed to help physicians iden-
tify life-threatened patients earlier, C-reactive protein
(CRP), an acute phase reactant, can be an alternative
severity index of acute OPP in addition to the scoring
system of Bardin et al [4,5].
MATERIALS AND METHODS
Consecutive patients with acute OPP, who were ad-
mitted to Kaohsiung Medical University Hospital be-
tween January 1995 and December 2005, were enrolled
in this study. A detailed history was taken from each
patient. Exclusion criteria included carbamate poison-
ing or severe pre-existing chronic health status. Age,
gender, chronic health status, type of OP ingested,
initial and subsequent serum AChE levels, clinical
presentation of OPP, dosage and duration of atropine,
palidroxime (PAM), and outcomes were retrospectively
analyzed by reviewing the medical records.
The diagnoses of acute OPP were based on the fol-
lowing criteria: (1) history of exposure to, or contact
with, insecticides; (2) characteristic clinical signs and
symptoms of OPP; (3) improvement of signs and symp-
toms after treatment with atropine or oximes; and (4)
decreased serum AChE activity (OPP was considered
if the lowest serum AChE activity was < 50% of the
laboratory minimum normal value) [1,6].
All patients received standard treatment for OPP,
including gastric lavage and activated charcoal via
nasogastric tubes. The patient’s body was cleaned with
soap and water immediately. Patients also received
intravenous infusions of atropine to counteract mus-
carinic effects, such as bronchial hypersecretion, lac-
rimation, and bradycardia. Atropine can be used as
an intermittent bolus infusion (1–2 mg per 2 hours) 
or continuous infusion (0.5–2 mg/hour). The goal of
atropine infusion was to keep the heart rate around
80–120 bpm with clear breathing sounds. PAM was
prescribed to patients who had OPP within 2 days.
We followed WHO recommendations for PAM ther-
apy (at least 30 mg/kg bolus followed by > 8 mg/kg/
hour infusion). Prior to treatment, blood samples were
collected for blood count, serum electrolytes, and
biochemistry analysis.
We graded patients with OPP according to the
grading system developed by Bardin et al [4,5]. Their
grading system groups OPP as mild, severe, or life-
threatening. Mild OPP is determined by a history of
exposure/intake with mild signs such as normal con-
sciousness, mild secretions, and little fasciculation.
Severe OPP is determined by a history of exposure/
intake with severe signs including altered conscious-
ness, copious secretions, and generalized fascicula-
tion. Life-threatening OPP is defined by a history of
exposure/intake with suicide attempt, stupor, PaO2 <
75 mmHg, and abnormal chest roentgenogram. This
grading system may not be applicable less than 8 hours
after poisoning. At least two criteria are required to
grade. If fewer criteria are present, then the previous
grade is used.
Serum AChE activity was measured by colorimetric
assays. The normal limits for serum AChE activity in
our laboratory ranged from 5,100 to 15,500 U/L.
Statistical analysis
Data were analyzed using JMP version 5.01 (SAS
Institute Inc., Cary, NC, USA) and presented as mean±
standard deviation. The χ2 test was used for statisti-
cal analysis. One-way analysis of variance (ANOVA)
was applied to assess differences among the groups.
For the non-normal distribution data, Wilcoxon/
Kruskal–Wallis test was used. Values of p < 0.05 were
considered statistically significant.
RESULTS
During the study period, 75 patients with OPP were
admitted to Kaohsiung Medical University Hospital.
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There were 25 female and 50 male patients. Their clini-
cal characteristics are summarized in Table 1.
Nearly all the patients were poisoned through the
gastrointestinal route, but three patients were poisoned
through the inhalational route. No patient was poi-
soned intravenously. More than 10 different kinds of
OP compounds were identified. The initial clinical pre-
sentations of the patients are shown in Table 1. Almost
all the OPP patients had muscarinic symptoms and
signs (66/75). The most frequent clinical signs were
bronchial hypersecretion (52%), tachycardia (47%),
miosis (45%), salivation (41%), and bradycardia (31%).
When we compared patients who had CNS disorders
with those without, we found that serum AChE levels
(983.4±195.8 U/L vs. 1,634.7±168.9 U/L, p=0.014) and
length of stay (14.9±1.6 days vs. 6.07±1.4 days, p=0.002)
were significantly different between the two groups.
According to the grading system of Bardin et al
[4,5], the 75 patients were divided into three groups
(mild, severe, life-threatening OPP). In these three
groups, serum AChE levels did not correlate to OPP
severity (p = 0.14). The life-threatening OPP group had
longer length of stay (p = 0.002), higher mortality (p =
0.013), and a higher infection rate (p=0.0006). The mild
OPP group had a lower incidence of intensive care
unit (ICU) admission and respiratory failure. The age
of OPP patients seemed to correlate to the severity of
this grading system (p = 0.04). All of the above results
are summarized in Table 2.
Initial serum CRP levels were taken from 40 pa-
tients when they arrived in our emergency room. The
normal range of CRP in our hospital is ≤ 6 mg/dL.
We found that initial serum AChE levels did not cor-
relate to serum CRP levels. The serum CRP levels of
the three groups (mild, severe, life-threatening OPP)
are shown in Table 3. The serum CRP level increased
in parallel to the severity grade of acute OPP (p <
0.001). Comparing the length of stay between the two
groups (CRP≤6 mg/dL vs. CRP>6 mg/dL), the length
of stay was significantly longer in the high CRP group
(5.8 ± 4.2 days vs. 16.2 ± 2.1 days, p = 0.03).
The mean total dose of atropine given was 27.0 ±
38.4 mg (range, 0–260 mg) and the duration of atropine
usage was 6 ± 4.7 days (range, 1–20 days). Thirty-three
patients did not receive atropine because symptoms
of muscarinic effects were not obvious in the initial
presentations. Concerning the use of atropine among
the different severity groups, the ratio of atropine use
increased as the grade became more severe (p = 0.003)
(Table 2). PAM was prescribed to 56 patients within
48 hours of poisoning. The average duration of PAM
was 5.5 ± 4.9 days and the mean total dose was 16.4 ±
12.4g. Prolonged PAM usage can increase serum AChE
levels, but the amplitude of the serum AChE increase
did not correlate with the duration of PAM use. There
was no significant difference in overall mortality  be-
tween patients with and without PAM usage (8.9% vs.
5.3%, p = 0.6). Among the three different OPP severity
groups, there was no significant improvement of mor-
tality in the life-threatening OPP group with PAM use
(5/31) or without PAM use (1/7) (p=0.9). PAM use also
did not shorten the length of stay among these differ-
ent OPP severity groups. For the respiratory failure
patients, mortality did not improve either with PAM
Table 1. Clinical features of 75 patients with organo-
phosphate poisoning*
Characteristics
Age (yr) 45.0 ± 17.2
(range, 6–79)
Gender, male/female 50/25
Attempted suicide 61 (81.3)
Atropine
Dosage 27.0 ± 38.4 mg
Duration of use 6 ± 4.6 d
PAM
Dosage 16.4 ± 12.4 g
Duration of use 5.5 ± 4.9 d
Mechanical ventilation 21 (28)
ICU admission 32 (42.7)
Mortality 6 (8)
Muscarinic signs/symptoms 66 (88)
Miosis 34 (45)
Bronchial hypersecretion 39 (52)
Diarrhea 18 (24)
Salivation 31 (41)
Bradycardia 23 (31)
Nicotinic signs/symptoms 35 (47)
Muscle fasciculations 5 (7)
Tachycardia 35 (47)
CNS signs/symptoms 32 (43)
Seizure 10 (13)
Unconsciousness 12 (16)
Confusion 20 (27)
*Data are expressed as mean ± standard deviation or n (%).
PAM = palidroxime; ICU = intensive care unit; CNS = central
nervous system.
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use (28%) or without PAM use (33%) (p = 0.84). How-
ever, days spent on ventilator support were decreased
in patients treated with PAM (6.7±1.9 days) compared
to those who were not (23.0±4.8 days) (p=0.004). There
was no significant difference in PAM use among the
three different OPP severity groups (Table 2).
Thirty-two patients were admitted to the ICU, with
mean ICU admission of 3.5 ± 6.1 days. The serum
AChE levels of ICU patients were lower than those 
of non-ICU patients (1,226.6 ± 200.4 U/L vs. 1,459.2 ±
77.6 U/L, p = 0.38). Endotracheal intubation and ven-
tilatory support were required in 21 patients, and 
all occurred within 72 hours. Comparison of serum
AChE levels in mechanically ventilated and non-
mechanically ventilated patients revealed significant
difference (916.6 ± 238.4 U/L vs. 1,539.3 ± 153.6 U/L,
p = 0.03). Two patients became ventilator-dependent
due to severe subsequent nosocomial infection. Three
patients died within 48 hours of ICU admission. The
causes of death were hepatic failure and acute renal
failure, and their serum AChE levels were quite vari-
able: 427.7, 50.4, and 1,092 U/L.
Biochemical analysis found hypokalemia in 10
patients (13.3%). Abnormal liver function was found
in nine patients (12%). Five patients had aspiration
pneumonia based on chest radiographs taken on the
day of admission. Eight patients had Q-Tc prolonga-
tion on electrocardiography (ECG). Normal anion-gap
metabolic acidosis was the prominent finding for the
initial blood gas analysis, and respiratory alkalosis was
the secondary finding.
DISCUSSION
OP compounds are used worldwide in agriculture 
as well as in household gardens. Ingestion of OP in
an attempt to commit suicide is a major problem, espe-
cially in developing countries, because the sale of these
items is over-the-counter in these countries. This ease
of availability of the compounds has resulted in a grad-
ual increase in accidental and suicidal poisoning. 
In our study, the rate of suicidal poisoning was 88%,
probably because of the uncontrolled sale and use of
these agents. It is also important to encourage farm-
ers to use protective masks during spraying of OP
to avoid accidental inhalation poisoning.
The inhibition of AChE activity leads to the accu-
mulation of acetylcholine at the synapses, causing
over-stimulation of muscarinic and nicotinic receptors.
Table 3. Relationship between C-reactive protein (CRP) and organophosphate poisoning severity
Mild (n = 16) Severe (n = 4) Life-threatening (n = 20) p†
CRP level (mg/dL)* 15.2 ± 15.8 60.3 ± 27.3 82.9 ± 10.9 0.004
Median (25%, 75%) 10.1 (4.8, 31) 62 (47.8, 71) 70 (38.7, 110.5)
*Data expressed as mean ± standard deviation; †analysis by Wilcoxon/Kruskal–Wallis test.
Table 2. Grade of organophosphate poisoning severity in 75 patients
Mild (n = 33) Severe (n = 4) Life-threatening (n = 38) p
Age (yr)* 39.4 ± 2.9 48.0 ± 8.4 49.6 ± 2.7 0.04†
LOS (d)* 5.9 ± 1.7 11.0 ± 4.7 13.9 ± 1.6 0.002†
AChE (U/L)* 1,656.9 ± 195.8 1,016.6 ± 562.3 1,146.6 ± 182.4 0.34‡
Median (25%, 75%) 2,034 (261.5, 2,695) 557.5 (184, 2,367.3) 674.5 (206.2, 1,854.5)
Mortality 0% 0% 15.8% 0.013§
ICU admission days* 0.6 ± 1.0 5.8 ± 2.8 5.6 ± 0.9 0.001†
Infection rate 21.2% 50% 63.1% 0.001§
Mechanical ventilator 9.1% 50% 44.7% 0.001§
Atropine use 18.1% 50% 89.5% 0.003§
PAM use 63.6% 100% 81.6% 0.07§
*Data expressed as mean ± standard deviation; †analysis by ANOVA; ‡analysis by Wilcoxon/Kruskal–Wallis test; §analysis by χ2 test.
LOS = length of stay; AChE = acetylcholinesterase; ICU = intensive care unit; PAM = palidroxime.
The onset, intensity, and duration of OPP are deter-
mined largely by the nature of the particular com-
pound and whether it exhibits reversible or irreversible
AChE binding. Muscarinic manifestations include ex-
cessive salivation, miosis, diarrhea, and bradycardia.
Nicotinic manifestations include muscle fasciculation
and tachycardia. OP can also influence the CNS and
result in seizures and altered consciousness. In this
study, the most frequent signs were bronchial hy-
persecretion (52%), tachycardia (47%), miosis (45%),
salivation (41%), and bradycardia (31%) (Table 1).
Patients in this study with CNS disorders had lower
serum AChE levels and longer length of stay than
those without CNS disorders. So, CNS involvement
is a poor prognostic factor for OPP patients and is
consistent with the conclusions made by Bardin and
van Eeden [4]. In addition, to stimulate the muscarinic
and nicotinic receptors of the CNS, there may need to
be higher acetylcholine levels by inhibition of AChE
activity with OPP than the peripheral receptors. How-
ever, retrospective analysis limited our results about
the exact onset, intensity and duration of clinical OPP
symptoms and signs.
Namba et al described a grading method for
patients with acute OPP based on clinical signs and
symptoms, as well as on the degree of inhibition of
serum AChE [7]. However, this proposed grading sys-
tem has proven to be unworkable in clinical practice
because serum AChE levels measured at the time of
admission do not correlate with the clinical severity of
poisoning [2,5,8,9]. Bardin et al [4,5] concluded that
clinical respiratory and CNS symptoms and signs are
the most important prognostic factors. They graded
patients into mild, severe, and life-threatening OPP
groups, and applied it to patients admitted to the ICU.
The life-threatening OPP group had unfavorable out-
comes even at lesser grades of severity. We adopted
this grading system to organize our OPP patients.
Among the three groups, the serum AChE level of
each group did not correlate to OPP severity. All cases
of mortality occurred in the life-threatening OPP group.
The life-threatening OPP group had longer length of
stay (p = 0.002), and higher mortality (p = 0.013) and
higher infection rates (p = 0.0006). Only four patients
were in the severe OPP group and this may be because
of the small sample size or disadvantages of classifica-
tion criteria. However, the value of this grading system
can help the physician to recognize subjects with seri-
ous OPP early, and permit their admission to an ICU.
Several other grading systems have also been eval-
uated. The APACHE II, III and SAPS II clinical scoring
tools seem to predict the severity of OPP, and may have
prognostic value [2,10,11]. Using continuous, online,
real-time spectral analysis of blood pressure and heart
rate signals can also be a sensitive alternate index for
earlier prediction of mortality in patients with acute
respiratory problems induced by acute OPP [12].
CRP, first described in 1930, is an acute phase
reactant and a marker of sepsis. In addition to infec-
tion, there are several other conditions that commonly
lead to substantial changes in CRP concentrations.
These include trauma, surgery, burns, tissue necrosis,
immunologically mediated inflammatory disease, and
advanced cancer [13,14]. In this study, initial serum
CRP levels were strongly correlated to the severity
grading of acute OPP (Table 3), but had no relation-
ship to serum AChE levels. Patients in higher serum
CRP level groups also had longer length of stay. In
addition to other grading systems, CRP can be a good
alternative index to evaluate the severity of acute OPP.
However, this was a retrospective analysis and we
did not have the data on serial serum CRP levels dur-
ing or following the management of the acute OPP
patients. A prospective study to confirm the value of
CRP may be needed.
Oximes reactivate AChE by removing the phos-
phoryl group. PAM is the oxime most often used
worldwide. The main therapeutic effect of PAM is the
recovery of neuromuscular transmission at the nico-
tinic synapses. In vitro experiments have shown that
oximes are effective in reactivating human AChE in-
hibited by OP compounds [15]. The clinical usefulness
of oximes has been challenged over the past 20 years
in many parts of the world as many have failed to 
see benefits in their practice [16]. Current evidence 
is insufficient for determining whether oximes are
harmful or beneficial in the management of acute OP
pesticide poisoning [17]. Peter et al also suggest that
oximes are associated with either a null effect or pos-
sible harm [18].
In our study, serum AChE level was increased 
by prolonged PAM usage, but the increase did not
have a significant correlation to the duration of PAM
usage. Among the three different OPP severity groups,
both the mortality and length of stay did not improve
with PAM usage. For OPP patients with respiratory
failure, PAM usage did not improve mortality, but it
did shorten the number of days spent on ventilator
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support. Although serum AChE levels did increase
with PAM usage, the mortality rates were not signifi-
cantly decreased by PAM usage. PAM can improve
ventilator weaning for OPP patients with respiratory
failure. However, the small sample size may render
the above results less significant.
Between the ICU and non-ICU patient groups,
lower serum AChE levels were found in the ICU group.
This result may come from the incorrect belief that
lower serum AChE levels indicate a higher severity of
acute OPP. The emergency room physicians may then
have arranged for intensive care for these patients.
Acute OPP-induced respiratory failure usually devel-
ops within 24 hours. In some case, it develops 24–96
hours after poisoning [3]. In this report, all the patients
developed respiratory failure within 72 hours after
poisoning, and most of them developed it within 24
hours. The initial serum AChE of the respiratory failure
group was significantly different from that of the non-
respiratory failure group. Only two patients became
ventilator-dependent and the causes of ventilator-
dependence were severe subsequent nosocomial infec-
tion and underlying disease. Although the need for
assisted ventilation is usually considered as an indica-
tor of illness severity in patients with acute OPP [3],
the mainstays of respiratory failure treatment is sup-
portive and to control the subsequent infection.
In our report, the ratio of OPP patients without
atropine use was high because there were no obvious
muscarinic effects in these patients. The high ratio may
be the result of either of the following two reasons:
(1) although some OPP patients did not present with
significant poisoning, they were still admitted for
observation and treatment because the exact onset
and intensity of clinical OPP symptoms, signs, and
comorbidities were unclear; (2) the ratio of muscarinic
effects of OPP, such as hypersecretion and bradycar-
dia, were not high, which seem comparable to the
atropine use ratio. The atropine use ratio (27/32) on
ICU admission of OPP patients was the same as in
other reports [2]. As OPP severity worsened, atropine
use also increased (Table 2). However, we included
less severe OPP patients in this study and this may
have influenced our results and mortality rate.
Mortality rates of acute OPP range from 10% to
20% and the causes of death were central respiratory
failure or the direct toxic effects of OPP [1,3]. The
usual causes of early death were chiefly related to
CNS depression [19], ventricular arrhythmias [20], or
respiratory failure [3]. Our mortality rate (8%) was
lower than other reports. Three patients developed
multiple organ failure within 2 days. The main causes
of mortality in these three patients were hepatic failure
and renal failure, which are unusual. The other patients
died of subsequent severe nosocomial infection.
In conclusion, low serum AChE levels support the
diagnosis of OPP, but no significant association is
present between the severity of poisoning and serum
AChE levels. The grading system of Bardin et al [4,5],
is very helpful for physicians to facilitate the recog-
nition of seriously poisoned subjects and to permit
their early admission to an ICU. Initial serum CRP
levels can be an excellent indicator of the severity of
acute OPP, but its role in following acute OPP is not
clear. Although the main management of acute OPP
is supportive and our recovery rate was above 90%,
atropine should be used as soon as possible to coun-
teract the muscarinic effects. PAM use still needs more
evidence to confirm its role in the management of
OPP. Physicians must be aware of the potential dan-
gers of respiratory failure, which could occur within
72 hours of OPP.
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